Y
Young Hwa Chung
Researcher at University of Ulsan
Publications - 68
Citations - 2033
Young Hwa Chung is an academic researcher from University of Ulsan. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatitis B virus. The author has an hindex of 21, co-authored 68 publications receiving 1803 citations. Previous affiliations of Young Hwa Chung include Asan Medical Center.
Papers
More filters
Journal ArticleDOI
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
Gi Ae Kim,Young-Suk Lim,Jihyun An,Danbi Lee,Ju Hyun Shim,Kang Mo Kim,Han Chu Lee,Young Hwa Chung,Yung Sang Lee,Dong Jin Suh +9 more
TL;DR: In this paper, the authors studied the long-term clinical outcome and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy in patients with chronic hepatitis B (CHB).
Journal ArticleDOI
Aberrant Epigenetic Modifications in Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein
In Young Park,Bo Hwa Sohn,Eunsil Yu,Dong Jin Suh,Young Hwa Chung,Je Ho Lee,Stefan J. Surzycki,Young Ik Lee +7 more
TL;DR: Targeted deregulation of DNMTs by HBx promotes both specific regional hypermethylation and global hypomethylation and may suggest a mechanism for epigenetic tumorigenesis during HBV-mediated hepatocarcinogenesis.
Journal ArticleDOI
Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
Kang Mo Kim,Jong Hoon Kim,Ik Soo Park,Gi-Young Ko,Hyun-Ki Yoon,Kyu-Bo Sung,Young-Suk Lim,Han Chu Lee,Young Hwa Chung,Yung Sang Lee,Dong Jin Suh +10 more
TL;DR: This study aimed to evaluate the therapeutic efficacy and safety of repeated transarterial chemoembolization with additional radiation therapy in hepatocellular carcinoma (HCC) with portal vein (PV) invasion.
Journal ArticleDOI
Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma.
Robert J. Clifford,Jinghui Zhang,Daoud Meerzaman,Myung Soo Lyu,Ying Hu,Constance M. Cultraro,Richard Finney,Jenny M. Kelley,Sol Efroni,Sharon Greenblum,Cu V. Nguyen,William Rowe,Sweta Sharma,Gang Wu,Chunhua Yan,Hongen Zhang,Young Hwa Chung,Jeong A. Kim,Neung Hwa Park,Il Han Song,Kenneth H. Buetow +20 more
TL;DR: Combined analysis of CNV, individual SNPs, and pathways suggest that HCC susceptibility is mediated by germline factors affecting the immune response and differences in T‐cell receptor processing.
Journal ArticleDOI
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Yee Chao,Young Hwa Chung,Guohong Han,Jung Hwan Yoon,Jijin Yang,Jianhua Wang,Guo Liang Shao,Byung Ik Kim,Teng Yu Lee +8 more
TL;DR: This study suggests that the combination of TACE and sorafenib is well tolerated and efficacious; the interrupted sorafinib dosing schedule may have contributed to a considerably lower AE profile than observed in other combination trials.